Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. (EGX: RMDA)

RMDA Revenue

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. had revenue of 763.23M EGP in the quarter ending September 30, 2024, with 39.86% growth. This brings the company's revenue in the last twelve months to 2.32B, up 30.32% year-over-year. In the year 2023, Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. had annual revenue of 1.92B with 29.54% growth.

• Revenue (ttm): 2.32B
• Revenue Growth: +30.32%
• P/S Ratio: 2.25
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 5.25B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	1.92B	438.40M	29.54%
Dec 31, 2022	1.48B	237.52M	19.06%
Dec 31, 2021	1.25B	286.27M	29.81%
Dec 31, 2020	960.17M	66.20M	7.41%
Dec 31, 2019	893.97M	88.46M	10.98%